Literature DB >> 28058555

Commentary on the Consensus Statement of the American Society of Breast Surgeons on Contralateral Prophylactic Mastectomy.

Sharyl J Nass1, Larissa Nekhlyudov2.   

Abstract

The increasing rate of contralateral prophylactic mastectomy (CPM) led the American Society of Breast Surgeons (ASBrS) to issue an evidence-based consensus statement on CPM, as well as a discussion guide that health care providers can use to facilitate shared decision making with patients considering CPM for unilateral breast cancer. This article suggests several ways to improve the discussion guide by eliciting patient values and preferences and by providing more current, detailed, and balanced information about the potential risks and benefits of CPM.

Entities:  

Mesh:

Year:  2017        PMID: 28058555     DOI: 10.1245/s10434-016-5758-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Patient decision aid for contralateral prophylactic mastectomy for use in the consultation: a feasibility study.

Authors:  J E Squires; D Stacey; M Coughlin; M Greenough; A Roberts; K Dorrance; M Clemons; J M Caudrelier; I D Graham; J Zhang; M Demery Varin; A Arnaout
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

2.  The relationship between contralateral prophylactic mastectomy and breast reconstruction, complications, breast-related procedures, and costs: A population-based study of health insurance data.

Authors:  Mary C Schroeder; Yu-Yu Tien; Lillian M Erdahl; Ingrid M Lizarraga; Brahmendra R Viyyuri; Sonia L Sugg
Journal:  Surgery       Date:  2020-08-18       Impact factor: 3.982

3.  Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.

Authors:  Patricia A Parker; Susan K Peterson; Yu Shen; Isabelle Bedrosian; Dalliah M Black; Alastair M Thompson; Jonathan C Nelson; Sarah M DeSnyder; Robert L Cook; Kelly K Hunt; Robert J Volk; Scott B Cantor; Wenli Dong; Abenaa M Brewster
Journal:  J Clin Oncol       Date:  2018-07-25       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.